Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Switching to Garadacimab From Current Prophylactic HAE Treatment
NCT06806657Phase 4Completed
- Sponsor
- CSL Limited
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Limited. Started Apr 2025; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06806657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806657.